Af­ter mul­ti­ple set­backs, Bris­tol My­ers scut­tles Op­di­vo pro­gram for brain tu­mor pa­tients af­ter fail­ing to pro­long ...

5 years ago
R&D
Pharma

Twist Bio­science plots its 'fac­to­ry of the fu­ture' in Ore­gon, seeks to ex­pand syn­thet­ic DNA client base

5 years ago
Pharma
Manufacturing

Al­ny­lam bids adieu to 2020 — and hel­lo to a slate of new ex­ecs; No­vavax taps Rick Crow­ley as COO

5 years ago
Peer Review

The fi­nal hours and days are tick­ing away on a $6B bet as dead­line looms on a sus­pense­ful FDA de­ci­sion

5 years ago
Bioregnum
Opinion

Nek­tar sells off roy­al­ties on its 2 ap­proved drugs for $150M in cash, re­dou­bling fo­cus on I-O can­di­dates

5 years ago
Deals

Warp Speed bets $356M to mass man­u­fac­ture a Mer­ck drug for se­vere Covid-19

5 years ago
Deals
Coronavirus

Trump par­dons Chris Collins, for­mer con­gress­man im­pris­oned for biotech in­sid­er trad­ing scan­dal

5 years ago
People

Covid-19 roundup: US and Pfiz­er strike deal for 100M more dos­es; NIH and part­ners cut crit­i­cal­ly ill pa­tients out of ...

5 years ago
Coronavirus

FDA slaps a hold on Voy­ager's lead gene ther­a­py over 'M­RI ab­nor­mal­i­ties'

5 years ago
Cell/Gene Tx
FDA+

News brief­ing: Atom­wise part­ners with Is­raeli in­cu­ba­tor; Bay­er col­lab­o­rates with Ve­r­a­cyte in thy­roid can­cer

5 years ago
News Briefing

More than 20 years in­to pro­teomics quest, So­ma­Log­ic keeps adding in­vestors as it nears a po­ten­tial pub­lic of­fer­ing

5 years ago
Financing

A neigh­bor­ly vis­it turns in­to a bid­ding war: How Dan Skovron­sky se­cured Eli Lil­ly's lat­est $1B buy

5 years ago
Deals

Kiniksa whiffs on ef­fi­ca­cy try­ing to re­pur­pose an RA pro­gram for Covid-19, but spins sur­vival 'trend­s' as a pos­i­tive

5 years ago
R&D
Coronavirus

Rhythm Phar­ma knocked off stride as mixed PhI­II obe­si­ty da­ta for its sole big drug look ‘meh’ to many

5 years ago
R&D

Dana-Far­ber backed Neo­morph hunts 'un­drug­gable' pro­teins with new round of in­vestor cash for hires, de­vel­op­ment

5 years ago
Financing

Amid a busy year and new lead­er­ship, Lon­za looks to build bio­con­ju­gates ca­pac­i­ty with Swiss ex­pan­sion set for 2022

5 years ago
Outsourcing
Manufacturing

A busy, buzzy Ver­tex finds a high-pro­file part­ner in the RNA-drug­ging world to launch a fresh dis­cov­ery ef­fort

5 years ago
Deals

Covid-19 roundup: Pfiz­er/BioN­Tech/Mod­er­na test vac­cines against new UK vari­ant; Ocu­gen strikes deal for US rights to ...

5 years ago
Coronavirus

FDA green­lights sec­ond Ebo­la treat­ment in three months, hand­ing new OK to Ridge­back­'s Eban­ga

5 years ago
FDA+

Pe­ter Thiel joins fund­ing round for pep­tide drug play­er in lat­est swing at emerg­ing biotech mar­ket

5 years ago
People
Financing

A 'sur­pris­ing' Phase III knocks back As­traZeneca, Am­gen's block­buster asth­ma am­bi­tions

5 years ago
R&D

Look­ing to build a 'd­ual sourcing' sup­ply chain, WuXi Bi­o­log­ics shells out $183M for Bay­er drug sub­stance plant

5 years ago
Deals
Outsourcing

News brief­ing: Glax­o­SmithK­line adds to flur­ry of deal­mak­ing; Take­da strikes $322M deal to of­fload a non-core ...

5 years ago
News Briefing

Months af­ter strik­ing SHP2 deal with Ab­b­Vie, Ja­co­bio pulls in $174M+ from Hong Kong IPO

5 years ago
Financing
China
First page Previous page 762763764765766767768 Next page Last page
A service from the Financial Times